Oxford Pharmascience hits stumbling block with OXPzero
20th Jul 2016 11:55
(ShareCast News) - Specialty pharmaceutical company Oxford Pharmascience updated the market on progress in its commercialisation efforts for its OXPzero Ibuprofen and OXPzero Naproxen compounds. The AIM-traded firm said the two variants leverage its proprietary OXPzero technology platform, which aim
Read moreLosses widen at Ozford Pharmascience
4th Mar 2016 16:03
(ShareCast News) - Oxford Pharmascience's losses widened in 2015, as the specialty pharmaceutical company spent more cash in a bid to move a number of products towards registration. The AIM-traded company's revenues jumped to £749,000, from £705,000 in 2014. Gross profit was down, however, to £158,0
Read moreOxford Pharmascience adds Reckitt stalwart to board
25th Feb 2016 15:42
(ShareCast News) - Oxford Pharmascience added a big name in the OTC medicines industry to its board on Thursday, announcing the appointment of Anand Sharma as a non-executive director with immediate effect. The AIM-traded medicine redevelopment firm said Sharma had worked in the pharmaceutical and c
Read moreOxford Pharmascience's OXPzero reaches second trial stage
12th Aug 2015 14:54
(ShareCast News) - AIM-listed Oxford Pharmascience said its OXPzero pain killer drug has reached the second stage of its clinical trial. In a statement the company said it believed preliminary data showed the ibuprofen had a clinical profile suitable for commercialisation. The company said the drug
Read moreCarnival Chairman reduces stake by around a quarter
26th Mar 2014 15:54
Micky Arison, the long-standing Chairman of cruise line operator Carnival Corp., docked a batch of shares earlier this week ahead of its better-than-expected first quarter trading update. Arison offloaded 525,348 at $40.09 each, reducing his stake to 104.52m shares. The group on Tuesday reported
Read moreOxford Pharmascience H1s indicate an 'exciting' redevelopment future
19th Sep 2013 13:16
Interim results from Oxford Pharmascience show the first small signs of an exciting future after it morphed into a drug re-development company. Group sales for the first half of 2013 were 47% higher than the same period last year at £501,000 and 7.5% higher than the whole of 2012. Chairman David
Read moreOxford Pharmascience completes next step in Safestat programme
28th Jan 2013 12:58
Oxford Pharmascience, a speciality pharmaceutical company, has successfully completed the formulation development for its Safestat drugs, Atorvastatin and Simvastatin. The developments continue the company's Safestat programme, which aims to re-formulate the widely used molecules of atorvastatin a
Read more